Sciarra Aeromed's purportedly sterile veterinary drug was contaminated and made under insanitary conditions, FDA says.
What happened
After serious adverse events, FDA conducted a multistate investigation, collected product samples, and inspected Sciarra Aeromed's facility in Carmel, NY, from February 9 to February 25, 2026. FDA's testing found viable fungal contaminants in a product labeled "sterile solution" and linked the contamination to an incident with the largest number of deaths associated with a veterinary medical product quality defect. The inspection found insanitary conditions, including missing sporicidal cleaning, environmental and personnel monitoring, smoke studies, and adequate media fills.
What FDA found
FDA's lab testing found viable fungi, including Purpureocillium lilacinum, in a product labeled "sterile solution," so it was not sterile and was adulterated and misbranded.
FD&C Act sections 501(a)(1), 501(c), and 502(a) (21 U.S.C. 351(a), 351(c), 352(a))The firm did not use a sporicidal cleaning agent (a cleaner that kills spores) and lacked cleaning validation or a written cleaning procedure for the ISO 7 and ISO 5 cleanroom areas.
FD&C Act section 501(a)(2)(A) (21 U.S.C. 351(a)(2)(A))The firm did not perform air sampling for living microbes in the ISO 5 area during production and had no environmental monitoring procedure.
FD&C Act section 501(a)(2)(A) (21 U.S.C. 351(a)(2)(A))The firm did not test operators' gloves or sterile garb for microbes during production and had no personnel sampling procedures.
FD&C Act section 501(a)(2)(A) (21 U.S.C. 351(a)(2)(A))The firm did not conduct static or dynamic smoke tests to show that airflow in the ISO 5 area protects the product from contamination.
FD&C Act section 501(a)(2)(A) (21 U.S.C. 351(a)(2)(A))The firm did not perform a sterility simulation fill for the worst-case vial size, and the facility had pest gaps, leaks, and nonsterile gowning that exposed skin.
FD&C Act section 501(a)(2)(A) (21 U.S.C. 351(a)(2)(A))
What FDA wants
FDA tells Sciarra Aeromed to take prompt action to correct the violations and, within 15 working days of receiving the letter, notify FDA in writing of specific steps, supporting documentation, and steps to prevent recurrence. If corrections cannot be completed in that time, the firm must state the reason for delay and when it will complete them.
Who should pay attention
- veterinarians who use or inject sterile veterinary drugs
- animal owners whose animals receive veterinary injectables
- distributors and clinics that stock sterile veterinary products
This is a summary. Read the original letter on fda.gov.